Aclaris Therapeutics Inc

1
NAS:ACRS (USA) Ā 
$ 1.15 -0.02 (-1.71%) 11:09 PM EST
At Loss
P/B:
0.52
Market Cap:
$ 81.56M
Enterprise V:
$ -34.99M
Volume:
845.80K
Avg Vol (2M):
1.56M
Also Trade In:
Volume:
845.80K
At Loss
Avg Vol (2M):
1.56M

Business Description

Aclaris Therapeutics Inc
NAICS : 541714 SIC : 8731
ISIN : US00461U1051
Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventiveĀ therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Name Current Vs Industry Vs History
Cash-To-Debt 279.59
Equity-to-Asset 0.8
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.95
Distress
Grey
Safe
Beneish M-Score -2.58
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 33.84
9-Day RSI 40.31
14-Day RSI 43.85
6-1 Month Momentum % -83.98
12-1 Month Momentum % -84.92

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.16
Quick Ratio 4.16
Cash Ratio 3.85
Days Sales Outstanding 5.24
Days Payable 195.78

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -16.3
Shareholder Yield % 0.33

Financials (Next Earnings Date:2024-05-08 Est.)

ACRS's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ACRS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return % Ā 

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return % Ā 

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Aclaris Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 31.249
EPS (TTM) ($) -1.27
Beta 0.09
Volatility % 101.62
14-Day RSI 43.85
14-Day ATR ($) 0.115208
20-Day SMA ($) 1.24
12-1 Month Momentum % -84.92
52-Week Range ($) 0.5902 - 11.12
Shares Outstanding (Mil) 70.93

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aclaris Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Aclaris Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Aclaris Therapeutics Inc Frequently Asked Questions

What is Aclaris Therapeutics Inc(ACRS)'s stock price today?
The current price of ACRS is $1.15. The 52 week high of ACRS is $11.12 and 52 week low is $0.59.
When is next earnings date of Aclaris Therapeutics Inc(ACRS)?
The next earnings date of Aclaris Therapeutics Inc(ACRS) is 2024-05-08 Est..
Does Aclaris Therapeutics Inc(ACRS) pay dividends? If so, how much?
Aclaris Therapeutics Inc(ACRS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1